A Riskier, But Perhaps More Profitable, CSO Business
At a time when much of the pharmaceutical outsourcing sector is struggling-with CROs particularly dragging over the last several years-the contract sales and marketing industry remains solid. One thing the CROs and CSOs do have in common is a desire to form risk-sharing partnerships with their clients that will bring them higher margins than traditional fee-for-service contracts. Last October, PDI's LifeCycle Ventures Inc. subsidiary inked a five-year agreement with Glaxo Wellcome Inc. for the exclusive US marketing, sales, and distribution rights for Ceftin, an oral antibiotic used in treating acute bacterial respiratory infections. PDI had to create an infrastructure with all the various commercial components, and since the deal, its share prices have been on a singularly impressive roller coaster ride. But PDI is once again looking for risk-sharing arrangements, although future deals may involve a more limited set of services than it is providing in connection with the Glaxo deal.
You may also be interested in...
The drug industry has accepted the need to outsource R&D--now, with sales productivity down, and the rising cost and risk of owning too much commercial infrastructure, why not outsource more of the sales effort, too? Big and small pharmas resist the idea but will eventually have to accept it--junior partners in licensing deals are insisting on roles in selling their own products, and Big Pharma must investigate cost-saving solutions.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.